Using exome-enriched RNA sequencing and machine learning, researchers tracked down a set of circulating maternal transcripts for predicting severe early-onset preeclampsia.
Under a two-year partnership, the companies plan to discover targets and disease mechanisms for infertility and pregnancy-related conditions, including preeclampsia.
The companies plan to explore opportunities to use Thermo Fisher's LC-MS instrumentation to develop tools to determine the risk for adverse pregnancy outcomes.
The partners will request samples from more than 2,500 existing and new participants in the foundation's Preeclampsia Registry for sequencing analysis.
The new assay is part of the company's prenatal and women's health offerings, but it is also developing a preeclampsia test and technology for gastrointestinal testing.
